Cleveland BioLabs Announces New US Patent Allowances for CBLB502 and CBLB612
News May 18, 2011
BioLabs, Inc. has announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its Protectan CBLB502 U.S. Patent Application Number 11/722,682, titled "Flagellin Related Polypeptides and Uses Thereof." Allowed claims cover composition of matter and use of CBLB502 for protecting a mammal from radiation.
The U.S. Patent and Trademark Office also issued a Notice of Allowance for the Company's Protectan CBLB612 patent application number 11/917,494, titled "Methods of Protecting against Apoptosis using Lipopeptides."
Allowed claims cover the various properties of Protectan CBLB612 and related compounds, including composition of matter and methods of use for protecting against apoptosis.
Yakov Kogan, Ph.D., MBA, Chief Operating Officer of Cleveland BioLabs, stated, "We are pleased to see the patent portfolio protecting our compounds and technology continue to expand in the US and around the world. These patents validate our unique approach to protection of healthy tissues from the impact of radiation and other acute stresses."
The Company also announced receipt of a Notice of Allowance from the New Zealand patent authority for a patent covering the various properties of Protectan CBLB612 and related compounds, including composition of matter and methods of use for protecting against apoptosis, as well as issuance of a patent for Protectan CBLB612 from the patent authority of South Africa, titled "Method for Increasing and Mobilizing Stem Cells."
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019